Corporate Magazine 2012 - Boehringer Ingelheim

4 NOTES TO THE CONSOLIDATED PROFIT AND LOSSSTATEMENTThe structure of the consolidated profit and loss statement was based on the total cost format.4.1 Net salesby business and business segment (in millions of EUR) 2012 2011Human Pharmaceuticals 13,080 11,676of which: Prescription Medicines 11,405 10,096Consumer Health Care 1,505 1,396Industrial Customers 162 178Other Sales 8 6Biopharmaceuticals 549 519Animal Health 1,062 97614,691 13,171by geographic region (in millions of EUR) 2012 2011Europe 4,194 4,037of which: Germany 1,033 950Americas 6,905 6,087of which: USA 5,550 4,820Asia / Australasia / Africa 3,592 3,047of which: Japan 2,111 1,83114,691 13,1714.2 Other operating incomeOther operating income includes income from currency translation of EUR 446 million (previous year:EUR 546 million).4.3 Material costs(in millions of EUR) 2012 2011Costs of raw material, supplies and goods for resale 1,377 1,231Expenditure on services 501 4481,878 1,67958Boehringer Ingelheim annual report 2012